Corbus Announces Positive Phase 1b Weight-Loss Data Showing For Oral Candidate CRB-913; Stock Up

Corbus Pharmaceuticals reported that its obesity drug, CRB-913, achieved 5% weight loss at 60mg after 12 weeks, with fewer gastrointestinal side effects than GLP-1 drugs, according to the company. The drug targets CB1 receptors to reduce hunger signals, with psychiatric side effects similar to GLP-1s, but minimal brain penetration. The company claims it may preserve muscle mass better than GLP-1s. The rise of obesity drugs is reshaping consumer food choices, regardless of future drug development

Corbus Pharmaceuticals (CRBP) stock rose 14.4% pre-market after reporting positive Phase 1b trial results for its obesity drug CRB-913, showing significant weight loss and a favorable safety profile. The company plans to present full data in November and initiate a Phase 2 study in 2027. The stock had been near its 52-week low before the announcement.

Corbus Pharmaceuticals (CRBP) shares rose 12% after reporting positive Phase 1b trial data for obesity drug CRB-913. The 60 mg dose showed 5% mean weight loss at 12 weeks. The trial enrolled 254 participants and tested three doses, all showing significant weight loss. The drug was generally well tolerated. Corbus plans to discuss further development with the FDA and start a Phase 2 study in early 2027.

Corbus Pharmaceuticals Holdings, Inc. (CRBP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update • Obtained FDA clearance to proceed with registrational study (TEMPO-1) of CRB-701 in 2L oropharyngeal cancer and expect to initiate enrollment in September 2026 • Concluded last

Corbus Pharmaceuticals (CRBP) reported updated Phase 1/2 data for CRB-701 in 2L oropharyngeal and cervical cancers, based on an April 1, 2026 cut with 317 patients. It cited ORR of 42.9% (median DOR 6.3 months, PFS 5.6) in OPSCC and 34.4% (DOR 8.0, PFS 4.3) in cervical cancer. The company plans registrational trials starting with TEMPO-1 in summer 2026; shares were down 12.79% pre-market to $9.90.

GSK has acquired global rights to a TCE program from Chimagen Biosciences for up to $750m, focusing on multiple myeloma. GSK will develop the unnamed drug, aiming for Phase I trials in 2027. This is GSK's second deal with Chimagen and reflects its renewed interest in oncology, a shift from its 2015 divestment. The TCE market is growing, with significant industry interest and a projected US market exceeding $10bn by 2032, according to market forecasters.